5-氨基-6H-蒽[9,1-cd][1,2]噻唑-6-酮 | 6937-00-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 中文名称: 5-氨基-6H-蒽[9,1-cd][1,2]噻唑-6-酮
• 英文名称: 5-Amino-Anthraisothiazolon
• 英文别名: 5-amino-anthra[9,1-cd]isothiazol-6-one；5-Amino-anthra[9,1-cd]isothiazol-6-on；5-Amino-6h-anthra[9,1-cd][1,2]thiazol-6-one；10-amino-14-thia-15-azatetracyclo[7.6.1.02,7.013,16]hexadeca-1(15),2,4,6,9,11,13(16)-heptaen-8-one
• CAS: 6937-00-4
• 化学式: C₁₄H₈N₂OS
• 分子量: 252.296
• InChiKey: VCLZHGSHIJOXRB-UHFFFAOYSA-N

物化性质

• 熔点：
  256 °C
• 沸点：
  429.6±37.0 °C(Predicted)
• 密度：
  1.539±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  84.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-氨基-6H-蒽[9,1-cd][1,2]噻唑-6-酮 、 1-氨基-9,10-二氧代-9,10-二氢蒽-2-甲酰氯 在 硝基苯 作用下， 生成 1-amino-9,10-dioxo-9,10-dihydro-anthracene-2-carboxylic acid-(6-oxo-6H-anthra[9,1-cd]isothiazol-5-ylamide)
  参考文献：
  名称：

  Anthraquinone derivatives

  摘要：

  公开号：

  US02149433A1
• 作为产物：
  描述：

  1-Amino-4-thiocyano-anthrachinon 在 sodium sulfide 、 sulfur 作用下， 生成 5-氨基-6H-蒽[9,1-cd][1,2]噻唑-6-酮
  参考文献：
  名称：

  DE216306

  摘要：

  公开号：

文献信息

• Methods for using JNK inhibitors for treating or preventing disease-related wasting
  申请人：Celgene Corporation

  公开号：US20040034084A1

  公开（公告）日：2004-02-19

  The present invention relates to methods useful for the treatment or prevention of disease-related wasting. The methods of the invention comprise the administration of an effective amount of a JNK Inhibitor. In one embodiment, the disease is HIV, AIDS, cancer, end-stage renal disease, kidney failure, chronic heart disease, obstructive pulmonary disease or tuberculosis. The methods can further comprise the administration of a therapeutic or prophylactic agent useful for the treatment or prevention of HIV, AIDS, cancer, end-stage renal disease, kidney failure, chronic heart disease, obstructive pulmonary disease, chronic infectious diseases (e.g., osteoarthritis and bacterial endocarditis), chronic inflammatory diseases (e.g., scleroderma and mixed connective tissue disease) or tuberculosis.

  本发明涉及治疗或预防疾病相关消瘦的方法。本发明的方法包括施用有效量的 JNK 抑制剂。在一个实施方案中，疾病是艾滋病毒、艾滋病、癌症、终末期肾病、肾衰竭、慢性心脏病、阻塞性肺病或肺结核。这些方法可以进一步包括施用对治疗或预防艾滋病毒、艾滋病、癌症、终末期肾病、肾衰竭、慢性心脏病、阻塞性肺病、慢性传染病（如骨关节炎和细菌性心内膜炎）、慢性炎症性疾病（如硬皮病和混合结缔组织病）或结核病有用的治疗剂或预防剂。
• Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
  申请人：——

  公开号：US20040087642A1

  公开（公告）日：2004-05-06

  The present invention relates to methods for treating, preventing, managing and/or modifying pain, comprising administering an effective amount of a JNK Inhibitor to a patient in need thereof. Specific embodiments encompass the administration of a JNK Inhibitor, alone or in combination with a second active agent and/or surgery or physical therapy. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

  本发明涉及治疗、预防、控制和/或改变疼痛的方法，包括向有需要的患者施用有效量的JNK抑制剂。具体的实施方案包括单独或与第二种活性剂和/或手术或物理疗法联合使用 JNK 抑制剂。本发明还公开了适用于本发明方法的药物组合物、单一单位剂型和试剂盒。
• Methods and compositions using JNK inhibitors for treatment and management of central nervous system injury
  申请人：Zeldis B. Jerome

  公开号：US20060122179A1

  公开（公告）日：2006-06-08

  Methods of treating, preventing and/or managing a central nervous system injury/damage and related syndromes are disclosed. Specific methods encompass the administration of a JNK inhibitor alone or in combination with a second active agent. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

  本文公开了治疗、预防和/或控制中枢神经系统损伤/损害及相关综合征的方法。具体方法包括单独施用 JNK 抑制剂或与第二种活性剂联合施用。本发明还公开了适用于本发明方法的药物组合物、单一剂型和试剂盒。
• Therapeutic methods for type I diabetes
  申请人：Davis J. Roger

  公开号：US20060223807A1

  公开（公告）日：2006-10-05

  The invention relates to the treatment and prevention of type I diabetes. More specifically, the invention relates to compounds that treat or prevent the body's immune system from destroying β-cells (i.e., insulin-producing cells in the pancreatic islets of Langerhans) by inhibition of JNK2, selective inhibition of JNK2, or inhibition of the expression of the MAPK9 gene or gene product. In one embodiment, the present invention contemplates the diagnosis, identification, production, and use of compounds which modulate MAPK9 gene expression or the activity of the MAPK9 gene product including but not limited to, JNK2, the nucleic acid encoding MAPK9 and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triple helix, antibody, and polypeptide molecules as well as small inorganic molecules. The present invention contemplates a variety of pharmaceutical formulations and routes of administration for such compounds.

  本发明涉及 I 型糖尿病的治疗和预防。更具体地说，本发明涉及通过抑制 JNK2、选择性抑制 JNK2 或抑制 MAPK9 基因或基因产物的表达来治疗或防止机体免疫系统破坏 β 细胞（即胰岛中的胰岛素分泌细胞）的化合物。在一个实施方案中，本发明考虑诊断、鉴定、生产和使用调节 MAPK9 基因表达或 MAPK9 基因产物活性的化合物，包括但不限于 JNK2、编码 MAPK9 的核酸及其同源物、类似物和缺失物，以及反义、核糖酶、三重螺旋、抗体和多肽分子以及无机小分子。本发明考虑了此类化合物的各种药物制剂和给药途径。
• Gattermann, Justus Liebigs Annalen der Chemie, 1912, vol. 393, p. 194
  作者：Gattermann

  DOI：——

  日期：——